Evidence map›Paper›PMID 41229623›Full record

ArticleEuropean journal of case reports in internal medicine2025

Palbociclib-Induced Apoptotic Colopathy: A Case Report and Review of the Literature.

Fernando A Díaz-Couselo, Santiago Flagel, Gisela Coliva, Christian Sanchez, Victoria Costanzo, Marcelo Zylberman

Abstract read
In one paragraph

Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fernando A Díaz-CouseloDepartment of Internal Medicine, Instituto Alexander Fleming, Buenos Aires, Argentina.
Santiago FlagelDepartment of Internal Medicine, Instituto Alexander Fleming, Buenos Aires, Argentina.
Gisela ColivaDepartment of Pathology and Cytology, Instituto Alexander Fleming, Buenos Aires, Argentina.
Christian SanchezDepartment of Gastroenterology, Instituto Alexander Fleming, Buenos Aires, Argentina.
Victoria CostanzoDepartment of Clinical Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
Marcelo ZylbermanDepartment of Internal Medicine, Instituto Alexander Fleming, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors (ribociclib, abemaciclib, and palbociclib) are standard first-line therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. While diarrhoea is a known adverse effect, severe gastrointestinal toxicity, particularly colitis, is rare and its histopathologic features are not well-characterized. Case report: We report the case of a 65-year-old woman with HR-positive, HER2-negative metastatic breast cancer who developed severe diarrhoea and significant weight loss during palbociclib treatment. Her prior treatment included adjuvant chemotherapy, radiotherapy, and letrozole, followed by first-line treatment for metastatic disease with fulvestrant and abemaciclib. Due to recurrent grade II diarrhoea on abemaciclib, she was switched to palbociclib. One year after initiating palbociclib, she presented with 6-10 daily bowel movements, 11 kg weight loss, anaemia, and hypoalbuminemia. Infectious aetiologies were excluded. Imaging revealed pancolitis, and a colonoscopy showed multiple deep ulcers. A rectal biopsy demonstrated chronic proctitis with increased epithelial apoptosis. Palbociclib was discontinued, and oral budesonide was initiated, which led to clinical and endoscopic remission. She remained asymptomatic on fulvestrant monotherapy for over 6 months. Conclusion: This rare case describes palbociclib-induced colitis with characteristic histopathologic findings of increased epithelial apoptosis, consistent with drug-induced apoptotic colopathy. To our knowledge, this is the first report of palbociclib-associated colitis with histological confirmation of apoptotic changes and successful treatment with budesonide. Clinicians should consider CDK4/6 inhibitors as a potential cause of severe gastrointestinal symptoms and recommend biopsy when the diagnosis is uncertain. LEARNING POINTS: Although diarrhoea is a common side effect, palbociclib can, in rare cases, cause severe colitis with deep ulcers at video colonoscopy; internists should be aware of this underrecognized adverse effect.Histologic findings of increased epithelial apoptosis can support the diagnosis of drug-induced apoptotic colopathy.Oral budesonide, commonly used in microscopic colitis, may be an effective treatment for CDK4/6 inhibitor-induced colitis, offering a well-tolerated therapeutic option.

Indexed as

apoptotic colopathybreast cancercyclin-dependent kinase inhibitorsdrug-induced colitisPalbociclib

Identifiers

PMID41229623
PMCPMC12604888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.